UBS Group’s ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) ECTE Stock Holding History

UBS Group’s Portfolio ECTE Stock Details ECTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-3,400	Closed	-$4K	–	8331
2016 Q2	$4K	Buy	3,400 +777	+30%	+$1.24K	﹤0.01%	7281
2016 Q1	$3K	Sell	2,623 -204	-7%	-$243	﹤0.01%	7265
2015 Q4	$4K	Buy	+2,827	New	+$4.54K	﹤0.01%	7832
2015 Q3	–	Sell	-1,615	Closed	-$3K	–	8911
2015 Q2	$3K	Buy	+1,615	New	+$2.7K	﹤0.01%	8136

Other funds holding ECTE

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

UBS Group's ECTE Position: Q3 2016 in Review

UBS Group sold out of ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) (ECTE) in Q3 2016, closing a stake of 3,400 shares — an estimated $4K sold.

UBS Group first reported a position in ECTE in Q2 2015 and held it in 4 quarters. The position peaked at $4K in Q2 2016. 2 funds tracked by Wall St. Rank hold ECTE as of Q3 2016.

UBS Group reported no remaining ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position as of Q3 2016 after selling out during the quarter.
UBS Group sold 3,400 ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) shares in Q3 2016, an estimated $4K.
UBS Group first reported a position in ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) in Q2 2015 and held it in 4 quarters.
UBS Group's ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position peaked at $4K in Q2 2016.
2 funds tracked by Wall St. Rank held ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) as of Q3 2016.

Based on UBS Group's 13F filing for Q3 2016, filed 14 Nov 2016.